Stock Analysis

Fisher & Paykel Healthcare Full Year 2024 Earnings: EPS Misses Expectations

Published
NZSE:FPH

Fisher & Paykel Healthcare (NZSE:FPH) Full Year 2024 Results

Key Financial Results

  • Revenue: NZ$1.74b (up 10% from FY 2023).
  • Net income: NZ$132.6m (down 47% from FY 2023).
  • Profit margin: 7.6% (down from 16% in FY 2023).
  • EPS: NZ$0.23 (down from NZ$0.43 in FY 2023).
NZSE:FPH Earnings and Revenue Growth May 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fisher & Paykel Healthcare EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 49%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Oceania.

Performance of the market in New Zealand.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Fisher & Paykel Healthcare's balance sheet.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.